Xtant Medical Holdings is a medical technology company focused on orthobiologics and spinal implant systems for orthopedic and neurological surgeons. Its third-quarter 2026 report lands during a period of significant transition. Following the late-2025 divestiture of non-core hardware assets and the loss of certain licensing revenue, the company has been pivoting toward its higher-margin biologics franchise while integrating the HEMOBLAST distribution agreement. Investors are watching closely to see whether that strategic shift can stabilize revenue and restore profitability, or whether cost pressures and mix changes will continue to weigh on margins. With liquidity tightening and the company now withdrawing guidance, this report carries outsized significance for how the market prices the turnaround story.
Xtant Medical Holdings reported third-quarter 2026 revenue of $24.3 million, a decline from $33.3 million in the same period a year earlier and below the consensus estimate of about $26.3 million. The company posted a net loss of $3.6 million, or $0.03 per basic and diluted share, versus net income of $1.3 million, or $0.01 per diluted share, in the prior-year quarter. Analysts had expected a narrower loss of roughly $0.02 per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Gross profit totaled $13.7 million, down from $22.0 million, as gross margin declined to 56.3% from 66.1%. Management attributed roughly 670 basis points of the decline to the cessation of high-margin wound-care licensing revenue and about 360 basis points to sales mix. Non-GAAP adjusted EBITDA swung to a loss of $1.5 million from positive $4.5 million a year ago.
A bright spot was the core biologics business, which grew 13% year over year to $19.3 million, while the new HEMOBLAST distribution contributed $2.2 million. Operating expenses declined to $16.7 million from $19.5 million, reflecting the simplified post-divestiture cost base.
The market responded sharply to the third-quarter miss and the withdrawal of guidance. XTNT shares fell by roughly 23% on the day of the announcement, extending a prolonged downtrend that has seen the stock lose a substantial portion of its value over the past twelve months. The combination of lower-than-expected revenue, a wider net loss, and the absence of a forward financial outlook removed key anchors that investors rely on to value the turnaround.
Sentiment was further pressured by the announcement that Xtant Medical Holdings would not host a conference call or webcast for the quarter, leaving the market with limited direct color from management. The strategic review introduces both potential upside—via possible transactions or operational improvements—and added uncertainty, as investors weigh the company's liquidity position and path back to profitability.
Looking ahead, the most important development for investors is the board-led strategic review. Because Xtant Medical Holdings has withdrawn its full-year 2026 guidance and will not provide revised figures during the review, near-term visibility into revenue and earnings is unusually limited. Any announcement regarding the scope or outcome of that review is likely to be a major catalyst.
Investors should also monitor the trajectory of the core biologics segment, which grew 13% year over year and 11% sequentially. Sustained growth here would signal that the pivot away from divested hardware assets is gaining traction, even as total revenue declines due to one-time divestitures and lost licensing income.
Liquidity and balance-sheet health remain key watchpoints. Cash and cash equivalents stood at $7.8 million at September 30, 2026, with total indebtedness of $22.0 million. With adjusted EBITDA turning negative, the company's ability to fund commercial investments and service debt will depend on stabilizing operations and, potentially, additional financing.
Finally, watch gross margin trends and the contribution from the HEMOBLAST distribution. The product mix shift away from high-margin licensing revenue has compressed profitability, and investors will look for evidence that biologics scale and cost discipline can offset that pressure over the next several quarters.
When reviewing earnings like this one from Xtant Medical Holdings, I often turn to Tickeron’s AI Screener to quickly filter for comparable names in the medical device space and spot emerging technical patterns. It streamlines the process of cross-checking fundamentals against peers and helps surface potential setups worth watching as new data comes in. This kind of tool adds efficiency without replacing core analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XTNT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 42 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XTNT as a result. In 79 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for XTNT entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where XTNT advanced for three days, in 195 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
XTNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.015) is normal, around the industry mean (4.142). P/E Ratio (-3.618) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.426) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. XTNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of surgical products
Industry MedicalNursingServices